23 results
Thumbnail

D3.265 - Biphasic anaphylaxis secondary to polyethylene glycol in a pediatric patient: a case report

Thumbnail

D3.268 - Chronic Allergen Exposure Induces Accumulation of IgE Plasma Cells in the Lung, Leading to Local IgE Antibody Production

Thumbnail

D3.269 - Drug-Induced Anaphylaxis in Children: A Comparative Analysis of Inpatient vs. Outpatient Settings

Thumbnail

D3.270 - A novel workflow for cell metabolomics: impact of anaphylaxis in a human endothelial system

Thumbnail

D3.272 - Safety and Efficacy of Vancomycin and Other Antimicrobial Drug Desensitization in Pediatric Patients

Thumbnail

D3.273 - Assessing Anaphylaxis in COVID-19 vaccines: Application of amended Brighton Collaboration Criteria

Thumbnail

D3.274 - Succesful Omalizumab Desensitization in Two Children with Severe Allergic Asthma and Cronic Spontaneous Urticaria

Thumbnail

D3.275 - Anaphylaxis caused by polyhexanide

Thumbnail

D3.276 - Acalabrutinib as premedication in platinum agents desensitization protocols: a case series supporting its role in enhancing tolerance with a repeatible efficacity

Thumbnail

D3.277 - Features of severe anaphylaxis in children, data from the Moscow Pediatric Register

Thumbnail

D3.364 - Effect of Omalizumab on Inflammatory and Immune Biomarkers in Mast Cell-Mediated Angioedema

Thumbnail

D3.358 - The impact of limited access to On-Demand Treatment for Hereditary Angioedema on Quality of life: a comparison between two income settings

Thumbnail

D3.359 - Study of olfaction in patients with chronic rhinosinusitis with nasal polyposis undergoing Mepolizumab treatment

Thumbnail

D3.362 - Use and safety of canakinumab during pregnancy

Thumbnail

D3.363 - Vitamin D3 deficiency promotes epithelial-to-mesenchymal transition and thus favours pulmonary fibrosis development in the murine model of hypersensitivity pneumonitis

Thumbnail

D3.365 - The role of anosmia in predicting biologic responsiveness for Chronic Rhinosinusitis with Nasal Polyposis

Thumbnail

D3.366 - Exploring potential predictive factors for time to response to Omalizumab treatment in a Romanian subset of patients with Chronic Spontaneous Urticaria

Thumbnail

D3.367 - Mental health, sexual functionality, quality of life, and patient experiences with chronic rhinosinusitis with nasal polyps at UNIMEQ-ORL in Bogotá, Colombia, 2022-2024: a mixed-methods study

Thumbnail

D3.368 - Analysis of discontinuation of omalizumab in patients with chronic spontaneous and/or inducible urticaria in a tertiary hospital in one year

Thumbnail

D3.436 - Advancing Equity in Food Allergy Prevention – Insights and Takeaways from CFAAR’s Summit for Advancing Equity in Food Allergy